Does Mavacamten Interact with Moderate To Strong Cyp2c19 Inducers?
CDI records a contraindicated classification for Mavacamten and Moderate To Strong Cyp2c19 Inducers. The stored summary is: Concomitant use decreases mavacamten exposure and may reduce efficacy. Risk of heart failure may increase upon discontinuation. Contraindicated. The mechanism involves cyp2c19 induction decreases mavacamten plasma concentrations. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Contraindicated
- Mavacamten Class
- Cardiac Myosin Inhibitor
- Management
- Do not take together
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
CYP2C19 induction decreases mavacamten plasma concentrations
What To Tell Your Doctor or Pharmacist
If you are taking Mavacamten and your doctor is considering prescribing Moderate To Strong Cyp2c19 Inducers (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask about alternative medications that do not interact with your current regimen
- Ask how frequently you should be monitored while these are co-prescribed
- Never stop or change either medication without first consulting your healthcare provider